BCAL Diagnostics develops BREASTEST Monitor for post-treatment breast cancer recurrence testing. BCAL Diagnostics Limited (ASX: BDX) develops BREASTEST Monitor, a blood-based diagnostic test designed to provide a simple, minimally invasive option for monitoring women for local recurrence of breast cancer following treatment. A routine blood test of this kind has the potential to support ongoing post-treatment monitoring with fewer invasive procedures, offering a meaningful benefit for patients and clinicians. BREASTEST Monitor is not yet commercially available as current results are preliminary. There are additional studies to complete prior to commercial launch. If you'd like further information about BCALs research studies, reach out to us at [email protected] Full announcement here: lnkd.in/gknK3RZM

BCAL Diagnostics Co-founder and Executive Chair Jayne Shaw share shares on @ausbiztv about the future of blood-based cancer diagnostics. BCAL has continued to execute on its commercialisation strategy, including expanding testing into the U.S. market through Sonic Healthcare. Improving access to earlier detection remains a key focus as we work to make advanced diagnostic testing more accessible for clinicians and patients globally. For more information earlydetection.com.au/

ASX Announcement: BCAL Diagnostics Signs Validation Agreement with Sonic Healthcare USA, for BreastestPlus™ Version 2.0 Key highlights • BreastestPlus Version 2 test validation agreement signed with Sonic Healthcare USA • Validation will be conducted in a CLIA-certified Sonic Reference Laboratory in Austin Texas • Sonic Healthcare USA is the 3rd largest pathology provider in the United States • The Laboratory Developed Test (LDT) pathway is the fastest and simplest US market entry route for BreastestPlus Version 2 • Successful validation represents a key milestone on the LDT pathway For more information:  api.investi.com.au/api/annou…

Are you a GP or healthcare professional interested in the future of early cancer detection and upper GI cancers? Join our upcoming clinical webinar hosted by Sydney Breast Clinic, in partnership with PanCare Foundation, EarlyDetection.com.au and Avantect. This session will explore the latest evidence in upper GI and pancreatic cancers, including clinical perspectives on diagnostic and treatment pathways, alongside the important role of consumer advocacy in shaping patient care. Featuring: • Dr Mark Buzza, PanCare Foundation – Head of Research, Innovation and Advocacy • A/Prof Manju Chandrasegaram, General and HPB Surgeon and Clinical Leader • Hosted by Renae Lopez, Chief Growth Officer, Sydney Breast Clinic -Wednesday, 3 June 2026 -6:30pm – 7:30pm AEDT - Online webinar Register here:  events.teams.microsoft.com/e…

BCAL Diagnostics (ASX: BDX) is pleased to announce a major milestone in expanding access to early cancer detection across Australia. BCAL’s early detection cancer referral forms are now accessible to 97% of Australian GPs through integration with Best Practice and Medical Director, alongside integration with Genie (Magentus), Australia’s leading specialist practice management platform. To further support patient access, BCAL has launched the EarlyDetection.com.au telehealth service in partnership with Medmate, led by Dr Martin A. Devitt. These initiatives establish a national referral infrastructure to support access to BCAL’s growing early cancer detection portfolio and scale commercial distribution across Australia. Additional milestones include: • Multi-Cancer Early Detection test launching June 2026 • Centre for Early Detection clinic opening in Sydney CBD for high-risk patients • Early Detection Australia platform now registered across New Zealand, the UK, USA, India and additional international markets Read the full ASX announcement here: lnkd.in/dFKc226G

At BCAL Diagnostics, we are proud to collaborate with ANSTO, one of Australia’s leading government research organisations, through the National Deuteration Facility. This partnership is supporting the development of bespoke deuterated lipid standards, strengthening the accuracy and reliability of our mass spectrometry-based diagnostic approach. Working with organisations of this calibre reinforces the scientific rigour behind our technology and our commitment to advancing more precise, accessible tools for early breast cancer detection, particularly for women with dense breast tissue where traditional imaging may be limited. ansto.gov.au/news/deuteratio…

Accelerating the commercial rollout of pancreatic and ovarian cancer testing across Australia. BCAL Diagnostics is pleased to announce the national expansion of our collection sites, expanding our collaboration with Sonic Healthcare and the Healius Limited Pathology network, improving access to testing services and supporting the early detection of pancreatic and ovarian cancer for more people across Australia. For more information, discuss with your GP. earlydetection.com.au/send-i…

ASX Announcement: BCAL submits MSAC application for Avantect™ Pancreatic Cancer early detection blood test Highlights • Application submitted to Medical Services Advisory Committee (MSAC) seeking Medicare Benefits Schedule (MBS) reimbursement for Avantect™ Pancreatic Cancer Test. • Commercial rollout underway with availability across NSW, QLD and Victoria via Sonic Healthcare and Healius pathology. • Strong early clinician and market engagement following January 2026 launch. • Clinical evidence base and advocacy support underpin reimbursement submission. Read more api.investi.com.au/api/annou…

Accelerating the commercial rollout of pancreatic and ovarian cancer testing across Australia. BCAL Diagnostics is pleased to announce the national expansion of our collection sites, expanding our collaboration with Sonic Healthcare and the Healius Limited Pathology network, improving access to testing services and supporting the early detection of pancreatic and ovarian cancer for more people across Australia. For more information, discuss with your GP. earlydetection.com.au/send-i…

BCAL Diagnostics has been featured in The Armchair Analyst’s latest article: “Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story.” It’s a timely reflection on what it takes to translate years of scientific research into clinically meaningful blood-based testing services used in real-world healthcare settings. After more than a decade of development, seeing our technologies move into clinical use is a significant milestone. As the article highlights, this journey is rarely simple but progress in diagnostics never is. What keeps us focused is the impact: supporting earlier, informed clinical decision-making, strengthening care pathways, and improving access through participating healthcare providers. Thank you to The Armchair Analyst and Jason Segal for telling our story. Read the full article here: thearmchairanalyst.com/p/cli…

Are you a doctor interested in the future of early cancer detection? Join our upcoming webinar hosted by @SydneyBreastClinic, in partnership with @ClearNoteHealth and Avantect. This session will discuss clinical insights to the Pancreatic and Ovarian cancer early detection testing that has been brought to Australia. 🗓️Thursday, 18th February 2026 at 6:30pm AEDT 📍Online. Register via lnkd.in/gPfybA9u

We’re proud to announce that testing is now available in Australia through the High Risk Clinic at The Sydney Breast Clinic, launched in partnership with Avantect. For more information or to book a consult lnkd.in/gmkW2DCj #BCALDiagnostics #EarlyDetection #PancreaticCancerDetection #OvarianCancerDetection #HighRiskClinic

World first pancreatic cancer blood test coming to Sydney. Following recent national coverage in The Australian, we’re proud to announce that the world first blood testing designed to detect pancreatic cancer will be available in Sydney from 19 January. Consultation with a physician and blood collection will be offered through the High-Risk Clinic at Sydney Breast Clinic, supporting individuals with elevated cancer risk through proactive, early detection. Pancreatic cancer is one of the most challenging cancers to diagnose early, often progressing silently until advanced stages. This blood- based analysis represents a major step forward, enabling earlier insights, earlier conversations, and better outcomes. Read the full article here: lnkd.in/gcV2qvYi Request an appointment lnkd.in/gmkW2DCj or email [email protected] #BCALDiagnostics #SydneyBreastClinic #EarlyDetection #PancreaticCancerDetection #OvarianCancerDetection #HighRiskClinic